# A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Study · id `cardio:ct-nct02260648` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02260648](<https://clinicaltrials.gov/study/NCT02260648>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02260648

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 149 participants.

## Technical summary

Registry record NCT02260648. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2018-10-09.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 149 participants (enrolled count; ClinicalTrials.gov record NCT02260648, source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02260648, source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)
- Primary completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02260648, source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)
- Completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02260648, source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)
- Results first posted: 2018-10-09 (ClinicalTrials.gov record NCT02260648, source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT02260648, source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02260648-2018-10-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
- Condition: Hypercholesterolemia
- Intervention (Drug): Evacetrapib
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: aa1aace1c46d8f54be4f7b3dd165bb29829d90a9c1e981102070916a06585162
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
